As of 2025-07-01, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (5.95) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.96 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -166.4%.
The range of the Relative Valuation is (5.75) - (6.46) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.5x - 25.3x | 23.9x |
| Forward P/E multiples | 17.2x - 28.2x | 22.7x |
| Fair Price | (5.75) - (6.46) | (5.95) |
| Upside | -164.2% - -172.2% | -166.4% |
| Date | P/E |
| 2025-06-27 | -36.63 |
| 2025-06-26 | -37.80 |
| 2025-06-25 | -38.12 |
| 2025-06-24 | -38.86 |
| 2025-06-23 | -38.78 |
| 2025-06-20 | -39.53 |
| 2025-06-18 | -38.98 |
| 2025-06-17 | -39.02 |
| 2025-06-16 | -40.27 |
| 2025-06-13 | -40.58 |
| 2025-06-12 | -40.70 |
| 2025-06-11 | -41.52 |
| 2025-06-10 | -43.09 |
| 2025-06-09 | -43.48 |
| 2025-06-06 | -43.20 |
| 2025-06-05 | -42.97 |
| 2025-06-04 | -43.20 |
| 2025-06-03 | -43.79 |
| 2025-06-02 | -41.99 |
| 2025-05-30 | -42.07 |
| 2025-05-29 | -42.58 |
| 2025-05-28 | -41.33 |
| 2025-05-27 | -42.23 |
| 2025-05-23 | -41.44 |
| 2025-05-22 | -40.66 |
| 2025-05-21 | -39.41 |
| 2025-05-20 | -40.43 |
| 2025-05-19 | -40.58 |
| 2025-05-16 | -40.07 |
| 2025-05-15 | -39.96 |
| 2025-05-14 | -38.55 |
| 2025-05-13 | -39.37 |
| 2025-05-12 | -40.46 |
| 2025-05-09 | -39.02 |
| 2025-05-08 | -38.82 |
| 2025-05-07 | -39.45 |
| 2025-05-06 | -40.19 |
| 2025-05-05 | -43.16 |
| 2025-05-02 | -34.95 |
| 2025-05-01 | -34.09 |
| 2025-04-30 | -34.63 |
| 2025-04-29 | -33.03 |
| 2025-04-28 | -32.56 |
| 2025-04-25 | -32.83 |
| 2025-04-24 | -32.17 |
| 2025-04-23 | -31.15 |
| 2025-04-22 | -30.60 |
| 2025-04-21 | -29.47 |
| 2025-04-17 | -28.96 |
| 2025-04-16 | -28.25 |